{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:00:02Z","timestamp":1787007602860,"version":"build-2736575974"},"reference-count":39,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Icosavax"},{"name":"AstraZeneca group"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2633021","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:09:37Z","timestamp":1772705377000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["A first-in-human Phase 1\/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adults"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-2328","authenticated-orcid":false,"given":"Ilse","family":"De Coster","sequence":"first","affiliation":[{"name":"University of Antwerp","place":["Antwerp, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5084-4696","authenticated-orcid":false,"given":"Isabel","family":"Leroux-Roels","sequence":"additional","affiliation":[{"name":"Ghent University and Ghent University Hospital","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchanamala","family":"Withanage","sequence":"additional","affiliation":[{"name":"University of Antwerp","place":["Antwerp, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Suykens","sequence":"additional","affiliation":[{"name":"University of Antwerp","place":["Antwerp, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"D\u2019Onofrio","sequence":"additional","affiliation":[{"name":"Ghent University and Ghent University Hospital","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[{"name":"Ghent University and Ghent University Hospital","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"van Damme","sequence":"additional","affiliation":[{"name":"University of Antwerp","place":["Antwerp, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Ciarlet","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Adams","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasima","family":"Rida","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Wen","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"MacDonald","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Price","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-5485","authenticated-orcid":false,"given":"Niranjan","family":"Kanesa-thasan","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000959"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00478-0"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0105-2022"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13031"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit839"},{"key":"e_1_3_5_7_1","unstructured":"Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET). Surveillance of RSV. 2025 Jul 8 [accessed 2025 Jul 10]. https:\/\/www.cdc.gov\/rsv\/php\/surveillance\/index.html."},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad031"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy991"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61153-x"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2311560"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae010"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209604"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac4241"},{"key":"e_1_3_5_15_1","unstructured":"US Food and Drug Administration (FDA). Abrysvo\u00ae (respiratory syncytial virus vaccine) prescribing information. 2025 Jul [accessed 2025 Oct 7]. https:\/\/www.fda.gov\/media\/168889\/download."},{"key":"e_1_3_5_16_1","unstructured":"US Food and Drug Administration (FDA). Mresvia (respiratory syncytial virus vaccine) prescribing information. 2025 Jun [accessed 2025 Oct 7]. https:\/\/www.fda.gov\/media\/179005\/download."},{"key":"e_1_3_5_17_1","unstructured":"European Medicines Agency (EMA). Arexvy summary of product characteristics. 2025 Sep [accessed 2025 Oct 7]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/arexvy-epar-product-information_en.pdf."},{"key":"e_1_3_5_18_1","unstructured":"European Medicines Agency (EMA). Abrsyvo summary of product characteristics. 2025 Apr [accessed 2025 Oct 8]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abrysvo-epar-product-information_en.pdf."},{"key":"e_1_3_5_19_1","unstructured":"European Medicines Agency (EMA). mResvia summary of product characteristics. 2025 Sep [accessed 2025 Oct 7]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mresvia-epar-product-information_en.pdf."},{"key":"e_1_3_5_20_1","unstructured":"US Food and Drug Administration (FDA). Arexvy (respiratory syncytial virus vaccine adjuvanted) prescribing information. 2025 Aug [accessed 2025 Oct 7]. https:\/\/www.fda.gov\/media\/167805\/download."},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1624007"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2508517"},{"key":"e_1_3_5_23_1","unstructured":"US Food and Drug Administration (FDA). PreHevbrio [Hepatitis B vaccine (recombinant)] prescribing information. 2024 Nov [accessed 2025 Jun 18]. https:\/\/www.fda.gov\/media\/154561\/download."},{"key":"e_1_3_5_24_1","unstructured":"US Food and Drug Administration (FDA). Vimkunya (chikungunya vaccine recombinant) prescribing information. 2025 Feb [accessed 2025 Jun 18]. https:\/\/www.fda.gov\/media\/185477\/download."},{"key":"e_1_3_5_25_1","unstructured":"US Food and Drug Administration (FDA). Cervarix [human papillomavirus bivalent (types 16 and 18) vaccine recombinant] prescribing information. 2019 Oct [accessed 2025 Jun 18]. https:\/\/www.fda.gov\/media\/78013\/download."},{"key":"e_1_3_5_26_1","unstructured":"US Food and Drug Administration (FDA). Gardasil\u00ae9 (human papillomavirus 9-valent vaccine recombinant) prescribing information. 2025 Mar [accessed 2025 Jun 18]. https:\/\/www.fda.gov\/media\/90064\/download."},{"key":"e_1_3_5_27_1","unstructured":"US Food and Drug Administration (FDA). Gardasil\u00ae [human papillomavirus quadrivalent (types 6 11 16 and 18) vaccine recombinant] prescribing information. 2025 Apr [accessed 2025 June 18]. https:\/\/www.fda.gov\/media\/186364\/download."},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15051109"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2331065"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav9033"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8818"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12080-1"},{"key":"e_1_3_5_33_1","unstructured":"Sciensano. Surveillance of acute respiratory infections. Epidemiological report seasons 2020-2021 and 2021\u20132022. 2024 Jul [accessed 2025 Oct 8]. https:\/\/www.sciensano.be\/sites\/default\/files\/end_of_season_2020-2022_report_nl_final_0.pdf."},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad546"},{"key":"e_1_3_5_35_1","unstructured":"European Centre for Disease Prevention and Control. European respiratory virus surveillance summary. [accessed 2025 Aug 6]. https:\/\/erviss.org\/."},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.168110"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00580-12"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf160"},{"key":"e_1_3_5_39_1","unstructured":"ClinicalTrials. A study to evaluate the safety and immunogenicity of IVX-A12 in participants of 60 to 85 years of age. Gov identifier: NCT05903183. 2024 Apr 12 [accessed 2025 Aug 6]. https:\/\/clinicaltrials.gov\/study\/NCT05903183."},{"key":"e_1_3_5_40_1","unstructured":"ClinicalTrials. A study of IVX-A12 in adults participants. Gov identifier: NCT06481579. 2025 Apr 27 [accessed 2025 Aug 6]. https:\/\/clinicaltrials.gov\/study\/NCT06481579."}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2633021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:09:44Z","timestamp":1772705384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2633021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2633021"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2633021","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2633021"}}